On March 6, 2025, the Board of Directors (the “Board”) of the Company appointed Michael Joseph (Joey) Hord, the Company’s current Sr. Vice President of Finance and Strategy, as the Company’s Chief Financial Officer, effective immediately following the filing of the Company’s Quarterly Report on Form 10-Q for the three months ending March 31, 2025 with the Securities and Exchange Commission (the “Transition Date”).
the Board of Directors (the “Board”) has elected Dr. Karen N. Madden, to join the Board effective February 28, 2025.
Appointed
Joseph E. McNeely
Director
DAVEY TREE EXPERT CO
Effective
2025-03-07
Filed
March 5, 2025, 6:59 PM ET
On February 28, 2025, the Board of Directors of The Davey Tree Expert Company (the “Company”) appointed Joseph E. McNeely to fill a vacancy on the Board, effective March 7, 2025.
On January 29, 2025, the Board of Directors of Isabella Bank Corporation (the "Corporation") appointed David B. Behen (age 55) to the Board of Directors of the Corporation and to the Board of Directors of Isabella Bank effective March 3, 2025.
Jeffrey A. Davis will continue in his current role as Chief Financial Officer through the filing of the Company’s Annual Report on Form 10-K for the fiscal year ended February 1, 2025 and until Mr. Glendinning assumes the role.
On March 4, 2025, the Board of Directors of Dollar Tree, Inc. (the “Company”) appointed Stewart Glendinning, age 59, as Chief Financial Officer of the Company, effective March 30, 2025.
On March 4, 2025, the Board appointed Sujay Kango as a Class II director of the Company and as a member of the Compensation Committee of the Board (the “Compensation Committee”), effective immediately after close of business on March 4, 2025.
On March 4, 2025, Tomas Kiselak, a member of the Board of Directors (the “Board) of Dianthus Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board effective as of the close of business on March 4, 2025.
On March 3, 2025, Peter Benz, a member of the Board of Directors (the “Board”) of Red Violet, Inc. (the “Company”) resigned effective March 4, 2025 from the Board and its committees to pursue other business commitments.
On March 4, 2025, the Company’s Board appointed Greg Strakosch to the Board, effective immediately to fill the vacancy created by Mr. Benz’s resignation.
the appointment of Thomas Krywe as the interim Chief Financial Officer, principal financial officer and principal accounting officer of the Company, effective on March 7, 2025
On the Exchange Effective Date, Paul Weibel notified the Company of his resignation from the Board of Directors of the Company (the “Board”), effective on such date.
Effective on March 4, 2025, Jennifer Phipps, the current Chief Accounting Officer of BrightSpring Health Services, Inc. (the “Company”), was promoted to Chief Financial Officer.
Ms. Phipps succeeds Jim Mattingly, whose transition and departure was not a result of any disagreement with the Company or any matter relating to the Company’s operations, policies or practices.
Departed
Sanjay Goel
Executive Vice President and President, Asia-Pacific
Marcello Apella was appointed as Chief Executive Officer and Roberto Castellazzi was appointed as President of each of IoTT World Inc. and GHST Sport Inc., the Company’s subsidiaries.
appointed Roberto Castellazzi as the Company’s Chief Executive Officer, Massimo Trebbi as President and Fabrizio Castellazzi as a director, following the resignations of Pierangelo Negri as a director, Roberto Castellazzi as President, Edoardo Berti Riboli as Chief Executive Officer, Paolo Sangiovanni as a Chief Financial Officer and Massimiliano Stella as Chief Information Officer
On March 5, 2025, the Board of Directors (“Board”) of Micron Technology, Inc. (the “Company”) appointed Anna Christine Simons and Teyin Mark Liu as members of the Board.
On March 5, 2025, the Board of Directors (“Board”) of Micron Technology, Inc. (the “Company”) appointed Anna Christine Simons and Teyin Mark Liu as members of the Board.
On March 3, 2025, Phillip A. Sharp, Ph.D. informed the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”) of his retirement from the Board, effective as of May 8, 2025.
On March 4, 2025, John Krenicki Jr. informed the Board of Directors (the “Board”) of Devon Energy Corporation (“Devon”) of his decision to retire from the Board at the end of his current term and not stand for re-election as a director at Devon’s 2025 annual meeting of stockholders (the “Annual Meeting”).
On March 1, 2025, the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”) increased the size of the Board from five to six directors and appointed Stelios Papadopoulos, Ph.D., as a Class I director of the Company
On March 5, 2025, GBLI announced that Stephen W. Ries, SVP, Senior Counsel & Head of Investor Relations, has stepped down from his position, effective February 28, 2025.
On March 4, 2025, Travis Whitfill notified the Board of Directors (the “Board”) of IN8bio, Inc. (the “Company”) of his resignation from the Board and its committees, effective as of May 9, 2025.
Departed
Jonathan J. Nudi
Group President, North America Pet, International, and North America Foodservice
On March 5, 2025, General Mills, Inc. (the “Company”) announced that Jonathan J. Nudi, Group President, North America Pet, International, and North America Foodservice, will retire from the Company effective June 30, 2025.
the Board appointed Julie A. Peffer and Richard A. Burnett as directors to fill two of those vacancies, with Ms. Peffer’s service to begin on March 1, 2025 and Mr. Burnett’s service to begin on May 3, 2025
the Board appointed Julie A. Peffer and Richard A. Burnett as directors to fill two of those vacancies, with Ms. Peffer’s service to begin on March 1, 2025
Andrew Siegel, who currently serves as Lead Independent Director of the Board, has been appointed to fill the role of independent Chair of the Board, effective as of the close of business March 5, 2025.
Mr. Kurtenbach will no longer serve as Chairman of the Board and Andrew Siegel, who currently serves as Lead Independent Director of the Board, has been appointed to fill the role of independent Chair of the Board, effective as of the close of business March 5, 2025.
On March 1, 2025, the Board of Directors (the “Board”) of Next Technology Holding Inc. (the “Company”) approved the appointment of Dr. Hongliang Liu (“Dr. Liu”) as the Chief Technical Officer of the Company, effective March 1, 2025.
Departed
Renmei Ouyang
Chief Executive Officer, President and Chairwoman
BAIYU Holdings, Inc.
Effective
2025-02-28
Successor
Ge Ouyang
Filed
March 5, 2025, 6:59 PM ET
On February 28, 2025, Renmei Ouyang, the Chief Executive Officer, President and Chairwoman of the board of directors (the “ Board ”) of BAIYU Holdings, Inc. (the “ Company ”), notified the Company of her decision to resign as the Chief Executive Officer, President, and a director of the Board of the Company.
Appointed
Ge Ouyang
Chief Executive Officer, President
BAIYU Holdings, Inc.
Effective
2025-03-04
Filed
March 5, 2025, 6:59 PM ET
On March 4, 2025, the Board appointed Ms. Ge Ouyang as the Chief Executive Officer and President of the Company and a member of the Board to serve until her successor has been duly appointed, or until her earlier death, resignation, or removal to fill the vacancies created by the resignation of Ms. Renmei Ouyang, effective March 4, 2025.
On March 3, 2025, Jordan R. Fasbender, the Executive Vice President, Chief Legal Officer and Secretary of iHeartMedia, Inc. (the “Company”) resigned from her positions with the Company, effective on or around April 1, 2025 (the “Effective Date”), to accept another position outside of the Company.
On February 20, 2025, Greg Carter, the Company’s Executive Vice President, Payment Acceptance, was promoted to Executive Vice President, Chief Revenue Officer.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.